The TL1A inhibitor market is rapidly advancing, driven by significant investments from major biopharmaceutical companies and growing confidence in its…
Registration open for premier international alternative investments gathering LONDON, Sept. 25, 2025 /PRNewswire/ — The Institute for Portfolio Alternatives (IPA)…